Log in

NASDAQ:ESPREsperion Therapeutics Stock Price, Forecast & News

$47.58
-3.46 (-6.78 %)
(As of 07/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$47.50
Now: $47.58
$52.40
50-Day Range
$39.75
MA: $45.94
$52.71
52-Week Range
$24.82
Now: $47.58
$76.98
Volume609,463 shs
Average Volume767,400 shs
Market Capitalization$1.31 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.13
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Read More
Esperion Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ESPR
CUSIPN/A
Phone734-887-3903

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$148.36 million
Book Value$0.73 per share

Profitability

Net Income$-97,170,000.00
Net Margins-5,492.02%

Miscellaneous

Employees76
Market Cap$1.31 billion
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive ESPR News and Ratings via Email

Sign-up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.

Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions

How has Esperion Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Esperion Therapeutics' stock was trading at $42.93 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ESPR shares have increased by 10.8% and is now trading at $47.58. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Esperion Therapeutics?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Esperion Therapeutics.

When is Esperion Therapeutics' next earnings date?

Esperion Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Esperion Therapeutics.

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics Inc (NASDAQ:ESPR) released its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported ($2.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.14) by $0.30. The biopharmaceutical company earned $1.80 million during the quarter, compared to analyst estimates of $0.39 million. Esperion Therapeutics had a negative return on equity of 627.38% and a negative net margin of 5,492.02%. Esperion Therapeutics's revenue for the quarter was down 98.8% on a year-over-year basis. During the same period in the prior year, the company posted $3.07 earnings per share. View Esperion Therapeutics' earnings history.

What price target have analysts set for ESPR?

13 Wall Street analysts have issued 12-month price targets for Esperion Therapeutics' stock. Their forecasts range from $42.00 to $191.00. On average, they anticipate Esperion Therapeutics' stock price to reach $81.46 in the next year. This suggests a possible upside of 71.2% from the stock's current price. View analysts' price targets for Esperion Therapeutics.

What are Wall Street analysts saying about Esperion Therapeutics stock?

Here are some recent quotes from research analysts about Esperion Therapeutics stock:
  • 1. According to Zacks Investment Research, "Esperion announced encouraging fourth quarter results, wherein earnings and revenues beat estimates. The company received approval for its two drugs, Nexletol and Nexlizet, in February 2020, which was a major boost. The company plans to launch Nexletol in March and Nexlizet in July. Regulatory applications seeking approval for these drugs are under review in Europe. Both candidates have achieved significant reduction in elevated LDL-C levels in hypercholesterolemia patients. The targeted area represents a significant opportunity. Shares have outperformed the industry in the past year. However, Esperion is heavily dependent on the successful commercialization of Nexletol and Nexlizet. The company will likely face stiff competition as its drugs target a crowded market. Esperion also has no other pipeline candidates." (3/26/2020)
  • 2. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating and lowering our target price to $70 which reflects a more conservative pre-CVOT BPA/combo sales ramp and higher SG&A assumptions. Even with our more conservative forecasts, we believe ESPR is undervalued at these levels (EV of ~$700 million) as we think the stock continues to reflect investor skepticism on the commercial opportunity for BPA/ combo and the company’s cash runway. We view BPA/combo as a clinically de-risked asset with two upcoming and believe BPA’s CVOT design portends a high probability of success. Further, our recent KOL checks have been consistent with our past discussions (see deep dive) in validating what we believe is a meaningful commercial opportunity for BPA/combo in the statin intolerant population." (9/17/2019)
  • 3. Northland Securities analysts commented, "We are now modeling $0.69 in non-GAAP EPS on $97.8 million in revenue for FY/19." (8/29/2019)

Has Esperion Therapeutics been receiving favorable news coverage?

Media coverage about ESPR stock has been trending very negative on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Esperion Therapeutics earned a daily sentiment score of -3.2 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Esperion Therapeutics.

Are investors shorting Esperion Therapeutics?

Esperion Therapeutics saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 9,370,000 shares, an increase of 15.4% from the June 15th total of 8,120,000 shares. Based on an average daily volume of 690,100 shares, the short-interest ratio is currently 13.6 days. Currently, 35.1% of the company's stock are sold short. View Esperion Therapeutics' Current Options Chain.

Who are some of Esperion Therapeutics' key competitors?

What other stocks do shareholders of Esperion Therapeutics own?

Who are Esperion Therapeutics' key executives?

Esperion Therapeutics' management team includes the following people:
  • Mr. Timothy M. Mayleben M.B.A., Pres, CEO & Director (Age 58)
  • Dr. Narendra D. Lalwani, Exec. VP of R&D (Age 66)
  • Mr. Richard B. Bartram, CFO & Corp. Sec. (Age 37)
  • Mr. Alexander Duke Schwartz, Sr. Director of Investor Relations
  • Ms. Marianne Andreach, Sr. VP

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

How do I buy shares of Esperion Therapeutics?

Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Esperion Therapeutics' stock price today?

One share of ESPR stock can currently be purchased for approximately $47.58.

How big of a company is Esperion Therapeutics?

Esperion Therapeutics has a market capitalization of $1.31 billion and generates $148.36 million in revenue each year. The biopharmaceutical company earns $-97,170,000.00 in net income (profit) each year or ($3.59) on an earnings per share basis. Esperion Therapeutics employs 76 workers across the globe.

What is Esperion Therapeutics' official website?

The official website for Esperion Therapeutics is www.esperion.com.

How can I contact Esperion Therapeutics?

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.